Worldwide, many patients with breast cancer are receiving abemaciclib and ET as first- or second-line treatment for HR + HER2-advanced or metastatic disease, and recently as adjuvant therapy for high-risk early-stage disease [27]. This evidence concerns the gene ERBB2 and breast cancer.